Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
WEBINAR | Mastering B-cell biomarker tracking in autoimmune therapy WATCH NOW!

The technology behind Bio-Rad’s custom recombinant antibodies

25 Oct 2017
Antibodies | ADCs

Take a look inside Bio-Rad’s custom recombinant antibody facility. Learn from our antibody experts how your requirements for specialized anti-biotherapeutic antibodies can become a reality through the use of HuCAL technology.


For more information on Bio-Rad, please click here.

Top content

  • Certara launches TFL Studio to accelerate scientific workflows
  • Webinar Q&A follow-up: Immunogenicity testing for gene therapy
  • Powering volumetric, non-invasive self-collection of first-void urine

Related tags

antibody Bio-rad biotherapeutics technology
Previous article Next article

Related articles

8 OCT 2013 GENERAL INTEREST
Predicting flu outbreaks – sensor technology holds promise
8 OCT 2014 MS (LC–MS/MS, HRMS, IMS)
Developing successful bioanalytical strategies for antibody–drug conjugates
15 APR 2014 CHROMATOGRAPHY
Interview with Hillel Brandes (Sigma Aldrich) on advances in bioseparation of large molecules
26 JUN 2014 GENERAL INTEREST
Separating enantiomers through the art of levitation
21 MAR 2011 CHROMATOGRAPHY
Biotherapeutic bioanalysis: a multi-indication case study review
2 SEP 2014 IMAGING
New imaging method may speed up diagnosis of malaria
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 Bioanalysis Zone